Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
This phase III clinical trial aimed to assess the safety and demonstrate the immunogenicity of a candidate freeze-dried purified Vero cell-based rabies vaccine (PVRV-WIBP) developed for human use. A cohort of 40 participants in stage 1 and 1956 subjects in stage 2 with an age range of 10–50 years we...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-01-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2023.2211896 |